Enjoy complimentary customisation on priority with our Enterprise License!
The tardive dyskinesia (TD) treatment market size is estimated to grow by USD 632.45 million at a CAGR of 4.73% between 2023 and 2028.
To early detection of growing cases of mental disorders, including schizophrenia, depression, and others, the tardive dyskinesia treatment is beneficial. In addition, TD is prompted by a long intake of medicines that block dopamine receptors in the brain to treat psychological disorders like schizophrenia. Furthermore, the prolonged intake of medications to treat mental illness can lead to TD, and the treatment will help patients revive.
To learn more about this report, Request Free Sample
The market share growth by the hospital pharmacy segment will be significant during the forecast period. The regulatory systems for pharmacies favor the dominance of hospital pharmacies in the market. Hospitals are significant healthcare locations where tardive dyskinesia treatments are consulted and carried out, and patients receive medical attention, which in turn fuels the demand for hospital pharmacies.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was valued at USD 1.05 billion in 2018. The growing cases of mental disorders across the world are further fueling the market. Hence, the growing cases of mental disorders and easy governance of hospital pharmacies are driving the demand for TD drugs from hospital pharmacies, which in turn will fuel the growth of the global tardive dyskinesia (TD) treatment market during the forecast period.
The Austedo and Ingrezza are used to treat the movement disorder chorea, which is associated with Huntington's Disease, and to treat tardive dyskinesia. These products are being used to block vesicular monoamine transporter type 2 (VMAT2) and reduce dopamine uptake in the brain. Although some reduction in symptoms may be noticed within a week or two, it can take up to 32 weeks (for TD) to have an effect. Thus, the high prevalence of tardive dyskinesia is anticipated to fuel the growth of the Austedo and Ingrezza segments, which in turn will drive the growth of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The market in North America is expected to witness significant growth due to increasing healthcare expenditure and the presence of well-established healthcare infrastructure.
Furthermore, anyone who has been treated for schizophrenia, bipolar disorder, schizoaffective disorder, anxiety, or depression and has taken or is taking antipsychotics is at high risk for developing TD. Hence, the growing cases of such bipolar disorders will lead to a higher prevalence of TD, which in turn will fuel the growth of the market in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market growth analysis report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abbott Laboratories: The company offers tardive dyskinesia treatment such as Aripiprazole or abilify drug.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key trends, and challenges.
Initiatives to spread awareness regarding treatment of tardive dyskinesia is one of the major market trends. Many governments are promoting the awareness of TD by launching awareness week programs. All 50 states in the US, Washington, DC, and various mental health advocacy organizations have recognized the first week of May (1-7) 2023 as TD Awareness Week. This awareness week addressed approximately 600,000 Americans living with involuntary movement disorder.
Furthermore, Teva Pharmaceutical Industries Ltd. launched the It's Not OK - It's TD national television advertising campaign to raise awareness of TD and Austedo (Deutetrabenazine) tablets in May 2021. Hence, such initiatives to spread awareness regarding treatment of tardive dyskinesia are expected to drive the market growth and trends during the forecast period.
Side effects related to tardive dyskinesia drugs is a challenge that affects market growth. The effective and FDA-approved drugs for the treatment of tardive dyskinesia are Austedo and Ingrezza. However, these drugs have certain side effects that can have negative impacts on human health. Agitation or restlessness, sleep problems, and swellings in the nose and throat are some of the side effects of Austedo observed in people who received the treatment for TD
Furthermore, boxed warning, long QT syndrome, neuroleptic malignant syndrome (NMS), and allergic reactions are some serious side effects that have been reported who received Austedo for the treatment of TD. Hence, the side effects related to tardive dyskinesia drugs are expected to negatively affect the growth of the market during the forecast period.
The market growth and forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The Tardive Dyskinesia Therapeutics Market addresses involuntary movements affecting the tongue, face, trunk, and extremities, often induced by long-term usage of psychiatric medications. Innovative treatments like valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO), both VMAT2 inhibitors, mitigate symptoms. Organizations like John Wiley & Sons, Inc. and the HealthWell Foundation offer financial support, aiding adults and children with prescription drugs through assistance programs for coinsurance, copayments, and deductibles. As a non-profit organization, HealthWell Foundation plays a crucial role in ensuring access to TD treatments, alleviating the financial burden on affected individuals and promoting their overall well-being.
The market research and growth report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Tardive Dyskinesia Treatment Market Scope |
|
Market Report Coverage |
Details |
Page number |
147 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.73% |
Market Growth 2024-2028 |
USD 632.45 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.22 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our market trends and analysis report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.